Aspergillosis encompasses a variety of clinical syndromes depending on host immunity factors.
It is caused by Aspergillus, an ubiquitous, soil-dwelling, filamentous fungus that grows on soil, food, dead leaves, household dust, etc. It grows best at 37ºC and the small spores are easily inhaled and deposited deep in the lungs.
The most common pathogens are Aspergillus fumigatus, A. flavus, A. niger and A. terreus.
Aspergilloma is a conglomeration of intertwined Aspergillus hyphae, fibrin, mucus and cellular debris within a pulmonary cavity or an ectatic bronchus.

Surgical Intervention

  • Surgical resection is the definitive treatment for single pulmonary aspergillomas and Aspergillus fungal ball of the paranasal sinus
  • Surgical excision has an important role in the invasion of bone, burn wounds, epidural abscesses and vitreal disease
    • May also be valuable when invasive pulmonary disease fails aggressive antifungal chemotherapy
  • Surgical resection of Aspergillus-infected tissue may be useful in patients with lesions that are near the great vessels or pericardium, lesions causing hemoptysis or uncontrolled bleeding from a single focus, and lesions causing erosion into the pleural space or ribs
  • Localized disease may benefit from debridement (eg sinus aspergillosis, cutaneous aspergillosis) 
  • Should also be considered in Aspergillus osteomyelitis, central nervous system aspergillosis, pericardial infection and endocarditis
  • Another relative indication is the resection of a single pulmonary lesion prior to intensive chemotherapy or hematopoietic stem cell transplantation (HSCT)
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 19 Jan 2018

The combination of ceftazidime and avibactam proved noninferior to meropenem in adults with nosocomial pneumonia, positioning it as a potential treatment option for this condition, results from the phase III REPROVE* trial show. Nonetheless, the combination was associated with a higher number of safety events compared with meropenem.

01 Jun 2016
Fluticasone furoate is superior to mometasone nasal spray in improving several perceived sensory attributes of allergic rhinitis patients, based on a multicentre, randomised, crossover, prospective study.
01 Aug 2014
Bilastine demonstrated high efficacy in the treatment of patients with allergic rhinitis, based on an analysis of publications.
15 Aug 2017
New drug applications approved by US FDA as of 1 - 15 August 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.